Compare FirstEnergy Corp. (FE) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FirstEnergy Corp. vs TG Therapeutics Inc — how do they compare? FirstEnergy Corp. trades at $46.79 (market cap $27.10B), while TG Therapeutics Inc trades at $49.64 (market cap $7.64B). The key difference: FirstEnergy Corp. is far larger — about 3.5× TG Therapeutics Inc's market cap, and FirstEnergy Corp. pays a 3.97% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| FE | TGTX | |
|---|---|---|
Market Cap | $27.10B | $7.64B |
Sector | Utilities | Health |
52-Week High | $51.91 | $59.06 |
52-Week Low | $42.83 | $26.94 |
Enterprise Value | $56.02B | $7.84B |
Dividend Yield | 3.97% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FirstEnergy (FE) trades at $46.81, showing minimal daily movement (+0.11%). The stock faces bearish technical signals with mixed earnings performance, missing Q4 2025 and Q2 2026 EPS estimates but beating Q1 2026. Revenue growth is steady, reaching $15.09B in 2025, with a net income margin of 6.86%. Recent news highlights institutional buying and strong Q2 2026 results driven by data center demand.
Outlook: FE benefits from rising electricity demand and a $36B grid investment plan, supporting long-term growth. Risks include high debt levels and regulatory pressures. Analysts are cautiously optimistic with a $52.67 price target (12% upside), but technical weakness suggests near-term consolidation.
TG Therapeutics (TGTX) trades at $49.66, up 1.02% on the day, with a bearish technical signal and recent earnings misses despite strong revenue growth. The company reported Q2 2026 revenue of $240 million and raised full-year BRIUMVI guidance to $950 million, but net income was impacted by manufacturing investments. Valuation ratios show a high P/E of 18.22 and EV/EBITDA of 56.26, while profitability metrics like ROE of 100.28% remain robust.
Outlook is mixed: strong product demand and raised revenue targets support growth, but earnings volatility and a bearish technical trend pose risks. Analyst consensus is bullish with an $63.75 price target, though legal investigations and competitive pressures require monitoring for stock investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About FirstEnergy Corp.
FirstEnergy is one of the largest investor-owned utilities in the United States with 10 regulated distribution companies across six mid-Atlantic and Midwestern states. FirstEnergy also owns and operates one of the nation's largest electric transmission systems with 24,000 miles of lines.
Read more on FE →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
